Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

4.180 +0.010 (+0.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 572,606
Open 4.190
Bid (Size) 4.000 (2)
Ask (Size) 4.180 (1)
Prev. Close 4.170
Today's Range 4.110 - 4.300
52wk Range 1.000 - 4.600
Shares Outstanding 25,938,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
From Immuneering Corporation
Via GlobeNewswire
Unusual volume stocks are being observed in Wednesday's session.
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill

Performance

YTD
+89.1%
+89.1%
1 Month
+76.4%
+76.4%
3 Month
+224.0%
+224.0%
6 Month
+114.4%
+114.4%
1 Year
+242.6%
+242.6%

More News

Read More
These stocks have an unusual volume in today's session
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Top movers in Wednesday's after hours session
Via Chartmill
Which stocks are experiencing notable movement on Wednesday?
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Here are the top movers in Wednesday's session.
Via Chartmill
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally
Via Stocktwits
These stocks are moving in today's session
Via Chartmill
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Via Chartmill
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Corporation Announces Grant of Inducement Award
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Immuneering Corporation
Via GlobeNewswire
Maximize Your Trades: Pre-Market Insights And Key Stock Breakdowns
Via Talk Markets
Topics ETFs Stocks / Equities
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 4.180
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 07/15/25 04:00 PM ET
What is the market capitalization of Immuneering Corporation - Class A Common Stock?
The market capitalization of Immuneering Corporation - Class A Common Stock is 108.42M
How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
Immuneering Corporation - Class A Common Stock has 108M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.